ES2195112T5 - Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo - Google Patents

Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo Download PDF

Info

Publication number
ES2195112T5
ES2195112T5 ES97901080.8T ES97901080T ES2195112T5 ES 2195112 T5 ES2195112 T5 ES 2195112T5 ES 97901080 T ES97901080 T ES 97901080T ES 2195112 T5 ES2195112 T5 ES 2195112T5
Authority
ES
Spain
Prior art keywords
preparation
nucleic acid
procedure
purified nucleic
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97901080.8T
Other languages
English (en)
Other versions
ES2195112T3 (es
Inventor
Wolfgang Kuhne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2195112(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of ES2195112T3 publication Critical patent/ES2195112T3/es
Application granted granted Critical
Publication of ES2195112T5 publication Critical patent/ES2195112T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
E97901080
23-09-2015
Listado de referencias
imagen6
7

Claims (1)

  1. imagen1
ES97901080.8T 1996-02-06 1997-01-24 Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo Expired - Lifetime ES2195112T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96101628 1996-02-06
EP96101628 1996-02-06
PCT/EP1997/000321 WO1997029113A2 (de) 1996-02-06 1997-01-24 Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung

Publications (2)

Publication Number Publication Date
ES2195112T3 ES2195112T3 (es) 2003-12-01
ES2195112T5 true ES2195112T5 (es) 2015-10-15

Family

ID=8222465

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97901080.8T Expired - Lifetime ES2195112T5 (es) 1996-02-06 1997-01-24 Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo

Country Status (12)

Country Link
US (8) US6750333B1 (es)
EP (1) EP0880536B2 (es)
JP (1) JP3442788B2 (es)
KR (1) KR100318808B1 (es)
CN (1) CN1121408C (es)
AT (1) ATE238321T1 (es)
AU (1) AU1444997A (es)
CA (1) CA2245576C (es)
DE (1) DE59709915D1 (es)
DK (1) DK0880536T4 (es)
ES (1) ES2195112T5 (es)
WO (1) WO1997029113A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746412B1 (fr) 1996-03-21 1998-06-12 Rhone Poulenc Rorer Sa Purification d'adn plasmidique de qualite pharmaceutique
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
DE19859703B4 (de) 1998-12-23 2009-10-29 Macherey, Nagel Gmbh & Co. Handelsgesellschaft Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens
DE19903507A1 (de) 1999-01-29 2000-08-10 Roche Diagnostics Gmbh Verfahren zur Herstellung endotoxinfreier oder an Endotoxin abgereicherter Nukleinsäuren und deren Verwendung
DE50008101D1 (de) * 2000-02-16 2004-11-11 Macherey Nagel Gmbh & Co Hg Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens
KR100356738B1 (ko) * 2000-09-07 2002-10-18 주식회사 삼양제넥스 염기성 단백질로부터 엔도톡신을 제거하는 방법
GB0028361D0 (en) * 2000-11-21 2001-01-03 Glaxo Group Ltd Method of separating extra chromosomal dna from other cellular components
GB0217963D0 (en) * 2002-08-02 2002-09-11 Cyclops Genome Sciences Ltd Purification of nucleic acids
DE10238630A1 (de) * 2002-08-19 2004-03-04 Macherey, Nagel Gmbh & Co. Handelsgesellschaft Verfahren zur Isolierung biologischer Makromoleküle sowie Vorrichtung zur Durchführung dieses Verfahrens
JP2005538717A (ja) 2002-09-13 2005-12-22 ヴァレンティス，インコーポレイテッド 核酸のプレパラティブスケールの精製のための装置および方法
US20080154029A1 (en) * 2004-04-02 2008-06-26 Nextec Gmbh Process For Manufacturing a Composite Sorbent Material For Chromatographical Separation of Biopolymers
DK2027272T3 (en) * 2006-05-24 2016-03-14 Scarab Genomics Llc Plasmid DNA PREPARATIONS AND METHODS FOR THE MANUFACTURE OF SAME
US20090186396A1 (en) * 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of phosphorylated and nonphosphorylated biomolecules by apatite chromatography
CN103255130B (zh) 2008-04-30 2015-12-23 斯特莱科生物有限公司 高纯度质粒dna制备物及其制备方法
US8822672B2 (en) 2009-05-26 2014-09-02 Eurogentec S.A. Method and device for producing and/or purifying polynucleotides and products obtainable thereof
RU2573894C2 (ru) 2009-08-06 2016-01-27 Дженентек, Инк. Способ усовершенствования процесса удаления вирусов при очистке белков
CN108148831A (zh) * 2018-01-15 2018-06-12 南京驯鹿医疗技术有限公司 一种无内毒素质粒大量制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3639949A1 (de) 1986-11-22 1988-06-09 Diagen Inst Molekularbio Verfahren zur trennung von langkettigen nukleinsaeuren
JPH01135792A (ja) 1987-11-20 1989-05-29 Mitsui Toatsu Chem Inc 核酸の分離・精製方法
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
DE59505786D1 (de) * 1994-02-07 1999-06-02 Qiagen Gmbh Verfahren zur abreicherung oder entfernung von endotoxinen
US5990301A (en) * 1994-02-07 1999-11-23 Qiagen Gmbh Process for the separation and purification of nucleic acids from biological sources
ES2227557T3 (es) 1994-07-15 2005-04-01 MERCK & CO., INC. Procedimiento para la purificacion a gran escala de plasmidos.
US5576196A (en) 1995-01-13 1996-11-19 Vical Incorporated Process for reducing RNA concentration in a mixture of biological material using diatomaceous earth
US6214586B1 (en) * 1997-12-08 2001-04-10 Genzyme Corporation Method for purifying plasmid DNA and plasmid DNA substantially free of genomic DNA
US6759394B2 (en) * 2001-07-26 2004-07-06 Board Of Supervisors Of La. State Un. & Agricultural And Mechanical College Cancer gene therapy based on translational control of a suicide gene

Also Published As

Publication number Publication date
AU1444997A (en) 1997-08-28
EP0880536B2 (de) 2015-08-05
DK0880536T4 (en) 2015-09-07
US20060165660A1 (en) 2006-07-27
ES2195112T3 (es) 2003-12-01
WO1997029113A2 (de) 1997-08-14
US20100074946A1 (en) 2010-03-25
US20140287026A1 (en) 2014-09-25
CA2245576A1 (en) 1997-08-14
US6750333B1 (en) 2004-06-15
JPH11509554A (ja) 1999-08-24
DK0880536T3 (da) 2003-08-11
US20110293708A1 (en) 2011-12-01
EP0880536A2 (de) 1998-12-02
US9421279B2 (en) 2016-08-23
JP3442788B2 (ja) 2003-09-02
US20130315985A1 (en) 2013-11-28
EP0880536B1 (de) 2003-04-23
CA2245576C (en) 2004-03-23
ATE238321T1 (de) 2003-05-15
US20130004562A1 (en) 2013-01-03
KR19990082308A (ko) 1999-11-25
DE59709915D1 (de) 2003-05-28
CN1210541A (zh) 1999-03-10
WO1997029113A3 (de) 1997-10-02
KR100318808B1 (ko) 2004-05-20
CN1121408C (zh) 2003-09-17
US20040209835A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
ES2195112T5 (es) Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo
ES2562022T3 (es) Estimulación del sistema inmunitario con polidextrosa
Lee et al. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials
AR019818A1 (es) Un inmunoconjugado de miostatina.
ES2165838T3 (es) Mejoras en o relativas a compuestos organicos.
FI875272A (fi) Baerarloesningsmedelssystem i tvao fas.
PT944396E (pt) Composicoes e processos para melhorar o funcionamento gastrointestinal
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
MA26466A1 (fr) Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation .
BR9814756A (pt) Composição sólida seca para liberação de droga, processo para a preparação da mesma, uso de um grande número de pequenas esferas que contêm uma matriz polimérica composta de um polietileno glicol ou de uma mistura de polietileno glicóis
AR042039A1 (es) Isomeros posicionales del ifn peg alfa 2 a
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
TW261615B (es)
ES2054612T3 (es) Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas.
DE60215548D1 (de) Anti-allergische pharmazeutische Zusammensetzung
DE3789673D1 (de) Selbstansaugendes Zufuhrsystem zur Verabreichung eines Heilmittels.
Romagnoli et al. Increase of mitotic activity in the colonic mucosa of patients with colorectal cancer
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE69384T1 (de) Pharmazeutische zubereitung fuer die intrarektale verabreichung von calcitonin und daraus hergestellte einzeldosisformen.
ATE312656T1 (de) Träger zur trennung von physiologischen flüssigkeiten mit verbesserter interner migration von therapeutischen substanzen
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica
BR0113328A (pt) Molécula de cintilador, processo para a preparação da mesma, lipossoma, micela, métodos para inserir uma ou mais moléculas de cintilador em um lipossoma e em uma célula, célula, kit, sistema de ensaio, composição, kit, e, uso de uma molécula de cintilador
Guardo et al. Pathology of Serratia marcescens mastitis in cattle
ITRM920535A1 (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
AR005559A1 (es) Construccion peptidica que tiene un efecto potencializador de la actividad biologica de la hormona del crecimiento, acido nucleico recombinante, composicion que contiene dicha construccion peptidica y uso de dicha composicion y de dicho acido nucleico recombinante.